A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

Inclusion Criteria Concurrent Medication: Allowed: * Antiretroviral therapy with AZT, ddI, ddC, or d4T. * Oral trimethoprim/sulfamethoxazole. * Dapsone. * Atovaquone. * Fluconazole. * Rifabutin. * Clarithromycin. Patients must have: * HIV seropositivity. * Mucocutaneous herpes simplex virus (HSV) infection confirmed by previous viral culture and persisting without improvement despite at least 10 days of acyclovir at a minimum dose of 1 g/day (oral) or 15 mg/kg/day (intravenous). * Measurable lesions. * Consent of parent or guardian if less than 18 years of age. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: Active medical problems sufficient to hinder study compliance or assessment of treatment effect. Concurrent Medication: Excluded: * Acyclovir. * Immunomodulators (such as corticosteroids or interferons). * Lymphocyte replacement therapy. * Biologic response modifiers. * Ganciclovir. * Foscarnet. * Vidarabine. * Topical trifluridine. * Other investigational drugs (except d4T). * Amphotericin. * Intravenous therapy for PCP. * Chemotherapeutic agents. Prior Medication: Excluded within 14 days prior to study entry: * Immunomodulators (such as corticosteroids or interferons). * Lymphocyte replacement therapy. * Biologic response modifiers. * Ganciclovir. * Foscarnet. * Vidarabine. * Topical trifluridine. * Other investigational drugs with potential anti-HSV activity. * Amphotericin. * Intravenous therapy for PCP. Excluded within 4 weeks prior to study entry: * Chemotherapeutic agents. Required: * At least 10 days of prior acyclovir at a minimum dose of 1 g/day (oral) or 15 mg/kg/day (intravenous). Substance abuse.